New study aims to outsmart relapse in aggressive blood cancers after transplant

NCT ID NCT07319793

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two ways of giving donor immune cells (DLI) after a stem cell transplant to prevent cancer from coming back in people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. One approach gives the cells early as a preventive measure, while the other waits for signs of remaining cancer. The trial will enroll 200 patients across multiple centers and track relapse rates, survival, and side effects like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donor lymphocyte infusion (DLI) with short-course immunosuppressive therapy (cyclosporine A or methotrexate)
What this could lead to: If successful, this could establish a better way to prevent cancer relapse after stem cell transplant, improving survival for patients with aggressive blood cancers.
What could go wrong: This is an early-stage study with no phase assigned, so results are uncertain. The infusions can cause serious side effects like graft-versus-host disease or severe infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES (MDS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.